Treatment with a gonadotropin-releasing-hormone analog and attainment of full height potential in a male monozygotic twin with gonadotropin-releasing hormone-dependent precocious puberty

Tomohiro Ishii, S. Sato, M. Anzo, G. Sasaki, Tomonobu Hasegawa, S. Tamai, N. Matsuo

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

We report on a pair of male monozygotic twins, one unaffected and the other affected with gonadotropin-releasing hormone (GnRH)-dependent precocious puberty, and discuss the role of treatment with a GnRH analog in the attainment of full height potential in GnRH-dependent precocious puberty. At 1.6 years of age, the affected twin was studied for tall stature (+3.8 SD), and was diagnosed as having GnRH-dependent precocious puberty due to a hypothalamic hamartoma of the tuber cinereum. He was treated with oral cyproterone acetate (110-170 mg/m2 daily) from 1.8 through 5.0 years of age, with oral cyproterone acetate and intranasal buserelin acetate (700-900 μg/m2 daily) from 5.0 through 7.5 years, and with intranasal buserelin acetate alone (1100-1400 μg/m2 daily) from 7.5 through 12.6 years. He attained a final height of 171.0 cm at 14.9 years of age (+0.10 SD) and his twin 170.0 cm at 15.3 years of age (-0.10 SD), with their target height being 174.5 ± 9.0 cm. Conclusion: This study indicates that GnRH analog treatment may preserve near full height potential in some patients with GnRH-dependent precocious puberty.

Original languageEnglish
Pages (from-to)933-935
Number of pages3
JournalEuropean Journal of Pediatrics
Volume158
Issue number11
DOIs
Publication statusPublished - 1999

Fingerprint

Precocious Puberty
Monozygotic Twins
Gonadotropin-Releasing Hormone
Buserelin
Cyproterone Acetate
Tuber Cinereum
Therapeutics

Keywords

  • Final height
  • GnRH analog
  • Hypothalamic hamartoma
  • Monozygotic twins
  • Precocious puberty

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

@article{3819ba46477e43d2a414ba3515c24722,
title = "Treatment with a gonadotropin-releasing-hormone analog and attainment of full height potential in a male monozygotic twin with gonadotropin-releasing hormone-dependent precocious puberty",
abstract = "We report on a pair of male monozygotic twins, one unaffected and the other affected with gonadotropin-releasing hormone (GnRH)-dependent precocious puberty, and discuss the role of treatment with a GnRH analog in the attainment of full height potential in GnRH-dependent precocious puberty. At 1.6 years of age, the affected twin was studied for tall stature (+3.8 SD), and was diagnosed as having GnRH-dependent precocious puberty due to a hypothalamic hamartoma of the tuber cinereum. He was treated with oral cyproterone acetate (110-170 mg/m2 daily) from 1.8 through 5.0 years of age, with oral cyproterone acetate and intranasal buserelin acetate (700-900 μg/m2 daily) from 5.0 through 7.5 years, and with intranasal buserelin acetate alone (1100-1400 μg/m2 daily) from 7.5 through 12.6 years. He attained a final height of 171.0 cm at 14.9 years of age (+0.10 SD) and his twin 170.0 cm at 15.3 years of age (-0.10 SD), with their target height being 174.5 ± 9.0 cm. Conclusion: This study indicates that GnRH analog treatment may preserve near full height potential in some patients with GnRH-dependent precocious puberty.",
keywords = "Final height, GnRH analog, Hypothalamic hamartoma, Monozygotic twins, Precocious puberty",
author = "Tomohiro Ishii and S. Sato and M. Anzo and G. Sasaki and Tomonobu Hasegawa and S. Tamai and N. Matsuo",
year = "1999",
doi = "10.1007/s004310051245",
language = "English",
volume = "158",
pages = "933--935",
journal = "European Journal of Pediatrics",
issn = "0340-6199",
publisher = "Springer Verlag",
number = "11",

}

TY - JOUR

T1 - Treatment with a gonadotropin-releasing-hormone analog and attainment of full height potential in a male monozygotic twin with gonadotropin-releasing hormone-dependent precocious puberty

AU - Ishii, Tomohiro

AU - Sato, S.

AU - Anzo, M.

AU - Sasaki, G.

AU - Hasegawa, Tomonobu

AU - Tamai, S.

AU - Matsuo, N.

PY - 1999

Y1 - 1999

N2 - We report on a pair of male monozygotic twins, one unaffected and the other affected with gonadotropin-releasing hormone (GnRH)-dependent precocious puberty, and discuss the role of treatment with a GnRH analog in the attainment of full height potential in GnRH-dependent precocious puberty. At 1.6 years of age, the affected twin was studied for tall stature (+3.8 SD), and was diagnosed as having GnRH-dependent precocious puberty due to a hypothalamic hamartoma of the tuber cinereum. He was treated with oral cyproterone acetate (110-170 mg/m2 daily) from 1.8 through 5.0 years of age, with oral cyproterone acetate and intranasal buserelin acetate (700-900 μg/m2 daily) from 5.0 through 7.5 years, and with intranasal buserelin acetate alone (1100-1400 μg/m2 daily) from 7.5 through 12.6 years. He attained a final height of 171.0 cm at 14.9 years of age (+0.10 SD) and his twin 170.0 cm at 15.3 years of age (-0.10 SD), with their target height being 174.5 ± 9.0 cm. Conclusion: This study indicates that GnRH analog treatment may preserve near full height potential in some patients with GnRH-dependent precocious puberty.

AB - We report on a pair of male monozygotic twins, one unaffected and the other affected with gonadotropin-releasing hormone (GnRH)-dependent precocious puberty, and discuss the role of treatment with a GnRH analog in the attainment of full height potential in GnRH-dependent precocious puberty. At 1.6 years of age, the affected twin was studied for tall stature (+3.8 SD), and was diagnosed as having GnRH-dependent precocious puberty due to a hypothalamic hamartoma of the tuber cinereum. He was treated with oral cyproterone acetate (110-170 mg/m2 daily) from 1.8 through 5.0 years of age, with oral cyproterone acetate and intranasal buserelin acetate (700-900 μg/m2 daily) from 5.0 through 7.5 years, and with intranasal buserelin acetate alone (1100-1400 μg/m2 daily) from 7.5 through 12.6 years. He attained a final height of 171.0 cm at 14.9 years of age (+0.10 SD) and his twin 170.0 cm at 15.3 years of age (-0.10 SD), with their target height being 174.5 ± 9.0 cm. Conclusion: This study indicates that GnRH analog treatment may preserve near full height potential in some patients with GnRH-dependent precocious puberty.

KW - Final height

KW - GnRH analog

KW - Hypothalamic hamartoma

KW - Monozygotic twins

KW - Precocious puberty

UR - http://www.scopus.com/inward/record.url?scp=0032820078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032820078&partnerID=8YFLogxK

U2 - 10.1007/s004310051245

DO - 10.1007/s004310051245

M3 - Article

VL - 158

SP - 933

EP - 935

JO - European Journal of Pediatrics

JF - European Journal of Pediatrics

SN - 0340-6199

IS - 11

ER -